Our recommendation is to compare approved-medicine dispensing arrangements first, establish a tested alternative fulfilment route, and evaluate clinic-stock purchasing only where the clinic has a specific operational reason to own inventory. Keep proposed compounding arrangements outside the commercial shortlist until clinical, legal and quality reviews establish their suitability.
This is a procurement recommendation—not a claim that one medicine or named pharmacy is best for every patient. FDA advises that compounded GLP-1 drugs should be used only when a patient's medical needs cannot be met by an FDA-approved drug. Compounded products do not undergo FDA's premarket review for safety, effectiveness and quality. (fda.gov)
For the procurement committee, three questions should precede any price comparison:
- What are we buying? Medicine inventory, dispensing services, prescription-routing technology, or assistance accessing a patient programme?
- Whose expenditure can we influence? The clinic's, the patient's, or an insurer's?
- What evidence supports this exact arrangement? Product, presentation, dispensing facility, destination state, payment route and intended use—not simply the supplier's brand name.
Evidence standard: Regulatory and programme facts below are sourced. Fit assessments, suggested contract terms, score weights and implementation steps are analyst recommendations. Public programme prices are not negotiated clinic quotations; no supplier's capacity, service performance or legal suitability has been independently audited for this report.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss